Ideaya Biosciences (NASDAQ: IDYA) — Perfil da empresa, notícias e dados financeiros
Ideaya Biosciences develops targeted therapeutics for cancer, focusing on precision medicine and addressing unmet oncology needs.
Ideaya Biosciences
Ideaya Biosciences (NASDAQ:IDYA) is a dynamic bio-pharmaceutical company dedicated to the discovery and development of targeted therapeutics for cancer. At the heart of their operations is a commitment to leveraging cutting-edge technologies and scientific approaches to address unmet needs in the oncology space. Ideaya Biosciences focuses on precision medicine, aiming to create treatments that can target specific genetic mutations and pathways that drive cancer growth. Their projects span a range of cancers, with an emphasis on developing both small molecule and immuno-oncology agents. The company's objectives are firmly rooted in the advancement of their clinical pipeline, aiming to progress through various stages of clinical trials efficiently, with the ultimate goal of bringing innovative cancer therapies to patients who need them most.
Resumo
Operações
Produtos e/ou serviços de Ideaya Biosciences
- A precision medicine focused on targeting patient populations with genetically defined cancers through synthetic lethality, including MAT2A for MTAP-deletion tumors.
- An immuno-oncology program aiming to enhance anti-tumor activity by targeting the immune system's ability to fight cancer.
- Development of a novel inhibitor for the treatment of solid tumors, focusing on the role of PARG in DNA repair.
- A partnership project to discover and develop targeted therapies across various oncology indications, leveraging synthetic lethality and immuno-oncology platforms.
- Collaboration on the development of a first-in-class therapy targeting GSK in specific cancer types, aimed at inhibiting tumor growth and progression.
- An advanced preclinical stage project focused on developing inhibitors targeting the Werner syndrome protein (WRN) helicase in cancers with microsatellite instability.
equipe executiva do Ideaya Biosciences
- Yujiro S. HataFounder, President, CEO & Chairman
- Joshua BleharskiChief Financial Officer
- Andres Ruiz BrisenoChief Accounting Officer
- Douglas B. SnyderChief Legal Officer
- Michael A. WhitePresident of Research & Development
- Darrin M. BeaupreChief Medical Officer
- Paul A. BarsantiChief Technology Officer
- Francine ZelayaSenior VP & Head of Human Resources
- Mick O'QuigleySenior Vice President of Medical Writing & Project Management
- Daniel A. SimonChief Business Officer
Últimas notícias sobre a Ideaya Biosciences
IDEAYA reports 60.8% response rate for IDE849
United StatesIDEAYA reports 57% eye preservation with darovasertib
United StatesIDEAYA promotes Michael White to R&D president
United StatesIDEAYA Biosciences doses first Phase 3 trial patient
United StatesIDEAYA prepares Phase 3 IDE849 lung cancer trial
United StatesIDEAYA Biosciences partners with Genentech on cancer trial
United States
Principais indicadores financeiros
Resultados divulgados pela Ideaya Biosciences, em USD.
- Cap. de mercado
- 3,3 bi
- Receita (TTM)
- 234,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.0
- Dividend yield
- —
- Margem de lucro
- -74.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 218,7 mi | -159,3 mi | -113,7 mi | |
| 7 mi | -327 mi | -274,5 mi | |
| 23,4 mi | -134,4 mi | -113 mi | |
| 50,9 mi | -62,5 mi | -54,8 mi |